Sarepta’s rough stretch might only coarsen
Sarepta Therapeutics is worth just about half of what it was as recently as July, and the latest news suggests things may not get any better in 2020.
As STAT’s Adam Feuerstein reports, a Sarepta rival called NS Pharma filed for FDA approval with a treatment for Duchenne muscular dystrophy. The NS therapy would treat DMD patients whose disease is caused by a mutation in the DNA sequence known as exon 53, the exact population Sarepta targeted with a drug that got rejected in August.
This sets up a situation in which Sarepta, which is yet to disclose a plan to address the FDA’s concerns, gets beat to the market. And, if the NS therapy is approved by the time Sarepta gets its act together, the company’s case for a second chance with the FDA might be that much less compelling.
Read more.
As STAT’s Adam Feuerstein reports, a Sarepta rival called NS Pharma filed for FDA approval with a treatment for Duchenne muscular dystrophy. The NS therapy would treat DMD patients whose disease is caused by a mutation in the DNA sequence known as exon 53, the exact population Sarepta targeted with a drug that got rejected in August.
This sets up a situation in which Sarepta, which is yet to disclose a plan to address the FDA’s concerns, gets beat to the market. And, if the NS therapy is approved by the time Sarepta gets its act together, the company’s case for a second chance with the FDA might be that much less compelling.
Read more.
.png)
No hay comentarios:
Publicar un comentario